S.M. O'Reilly

1.8k total citations
26 papers, 1.2k citations indexed

About

S.M. O'Reilly is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, S.M. O'Reilly has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Pathology and Forensic Medicine. Recurrent topics in S.M. O'Reilly's work include Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (6 papers) and Advanced Breast Cancer Therapies (3 papers). S.M. O'Reilly is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (6 papers) and Advanced Breast Cancer Therapies (3 papers). S.M. O'Reilly collaborates with scholars based in United Kingdom, Belgium and United States. S.M. O'Reilly's co-authors include M A Richards, E.S. Newlands, R.D. Rubens, R.D. Rubens, Michael A. Richards, Paul D. Lewis, R D Illingworth, Peter G. Richards, M.G. Glaser and Iain Colquhoun and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

S.M. O'Reilly

25 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.M. O'Reilly United Kingdom 14 641 354 294 293 225 26 1.2k
Catharina Wenzel Austria 22 979 1.5× 403 1.1× 376 1.3× 154 0.5× 221 1.0× 48 1.4k
Hwee‐Yong Yap United States 18 765 1.2× 174 0.5× 398 1.4× 271 0.9× 204 0.9× 31 1.3k
J J Costanzi United States 20 641 1.0× 272 0.8× 283 1.0× 158 0.5× 295 1.3× 36 1.2k
R Plagne France 17 560 0.9× 145 0.4× 144 0.5× 221 0.8× 282 1.3× 100 1.3k
Alan Barge United Kingdom 14 819 1.3× 166 0.5× 250 0.9× 183 0.6× 411 1.8× 21 1.5k
H. Y. Yap United States 19 933 1.5× 535 1.5× 451 1.5× 133 0.5× 117 0.5× 42 1.4k
Malgorzata Tuxen Denmark 18 687 1.1× 318 0.9× 282 1.0× 78 0.3× 394 1.8× 33 1.8k
Reginald P. Pugh United States 19 581 0.9× 221 0.6× 269 0.9× 116 0.4× 217 1.0× 34 1.1k
Ursula Pluschnig Austria 23 867 1.4× 284 0.8× 550 1.9× 83 0.3× 124 0.6× 69 1.4k
Corinne Veyret France 19 704 1.1× 500 1.4× 391 1.3× 138 0.5× 203 0.9× 62 1.1k

Countries citing papers authored by S.M. O'Reilly

Since Specialization
Citations

This map shows the geographic impact of S.M. O'Reilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.M. O'Reilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.M. O'Reilly more than expected).

Fields of papers citing papers by S.M. O'Reilly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.M. O'Reilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.M. O'Reilly. The network helps show where S.M. O'Reilly may publish in the future.

Co-authorship network of co-authors of S.M. O'Reilly

This figure shows the co-authorship network connecting the top 25 collaborators of S.M. O'Reilly. A scholar is included among the top collaborators of S.M. O'Reilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.M. O'Reilly. S.M. O'Reilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Misra, Vivek, et al.. (2014). Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres. Supportive Care in Cancer. 22(8). 2033–2037. 5 indexed citations
2.
McIllmurray, M B, et al.. (2008). Vinorelbine and Infusional 5-fluorouracil in Anthracycline and Taxane Pre-treated Metastatic Breast Cancer. Clinical Oncology. 20(2). 152–156. 8 indexed citations
3.
4.
Talbot, Denis, Vladimir Moiseyenko, Simon Van Belle, et al.. (2002). Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. British Journal of Cancer. 86(9). 1367–1372. 157 indexed citations
5.
6.
Marshall, Ernest, et al.. (2000). Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients. Supportive Care in Cancer. 8(3). 198–202. 10 indexed citations
7.
Harte, Robert, Julian C. Matthews, S.M. O'Reilly, & Pat Price. (1998). Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil.. PubMed. 39(8). 1370–6. 11 indexed citations
8.
Newlands, E.S., S.M. O'Reilly, M.G. Glaser, et al.. (1996). The charing cross hospital experience with temozolomide in patients with gliomas. European Journal of Cancer. 32(13). 2236–2241. 122 indexed citations
9.
Bower, Mark, C. Brock, T. Gulliford, et al.. (1996). A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma. Cancer Chemotherapy and Pharmacology. 38(1). 106–109. 7 indexed citations
10.
O'Reilly, S.M., E.S. Newlands, M Brampton, et al.. (1993). Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. European Journal of Cancer. 29(7). 940–942. 231 indexed citations
11.
Smith, David B., S.M. O'Reilly, & E.S. Newlands. (1993). Current approaches to diagnosis and treatment of gestational trophoblastic disease. Current Opinion in Obstetrics & Gynecology. 5(1). 84–91. 11 indexed citations
12.
O'Reilly, S.M. & G.J.S. Rustin. (1993). Mismanagement of choriocarcinoma due to a false low HCG measurement. International Journal of Gynecological Cancer. 3(3). 186–188. 19 indexed citations
13.
O'Reilly, S.M. & M A Richards. (1992). Is DNA flow cytometry a useful investigation in breast cancer?. European Journal of Cancer. 28(2-3). 504–507. 21 indexed citations
14.
O'Reilly, S.M., et al.. (1992). Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours. Annals of Oncology. 3(2). 163–164. 14 indexed citations
15.
O'Reilly, S.M., R.D. Rubens, M A Richards, & Richard S. Camplejohn. (1992). DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. European Journal of Cancer. 28(2-3). 681–683. 60 indexed citations
16.
Richards, M A, S.M. O'Reilly, Anthony Howell, et al.. (1990). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial.. Journal of Clinical Oncology. 8(12). 2032–2039. 77 indexed citations
17.
O'Reilly, S.M., RS Camplejohn, D M Barnes, et al.. (1990). Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.. Journal of Clinical Oncology. 8(12). 2040–2046. 99 indexed citations
18.
O'Reilly, S.M. & Martin Richards. (1990). Node negative breast cancer.. BMJ. 300(6721). 346–348. 7 indexed citations
19.
O'Reilly, S.M., Richard S. Camplejohn, Rosemary R. Millis, R.D. Rubens, & Michael A. Richards. (1990). Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. European Journal of Cancer and Clinical Oncology. 26(10). 1035–1038. 31 indexed citations
20.
O'Reilly, S.M., Michael A. Richards, & R.D. Rubens. (1990). Liver metastases from breast cancer: The relationship between clinical, biochemical and pathological features and survival. European Journal of Cancer and Clinical Oncology. 26(5). 574–577. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catharina Wenzel Breakdown of academic impact, for papers by Hwee‐Yong Yap Breakdown of academic impact, for papers by J J Costanzi Breakdown of academic impact, for papers by R Plagne Breakdown of academic impact, for papers by Alan Barge Breakdown of academic impact, for papers by H. Y. Yap Breakdown of academic impact, for papers by Malgorzata Tuxen Breakdown of academic impact, for papers by Reginald P. Pugh Breakdown of academic impact, for papers by Ursula Pluschnig Breakdown of academic impact, for papers by Corinne Veyret
Rankless by CCL
2026